EBA
ALLO icon

Eagle Bay Advisors’s Allogene Therapeutics ALLO Stock Holding History

Eagle Bay Advisors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-216
Closed -$460 – 150
2024
Q4 		$460 Hold
216
– – ﹤0.01% 965
2024
Q3 		$605 Hold
216
– – ﹤0.01% 1309
2024
Q2 		$503 Hold
216
– – ﹤0.01% 959
2024
Q1 		$966 Hold
216
– – ﹤0.01% 929
2023
Q4 		$693 Hold
216
– – ﹤0.01% 794
2023
Q3 		$685 Hold
216
– – ﹤0.01% 812
2023
Q2 		$1.07K Buy
216
+108
+100% +$584 ﹤0.01% 801
2023
Q1 		$534 Hold
108
– – ﹤0.01% 868
2022
Q4 		$679 Hold
108
– – ﹤0.01% 860
2022
Q3 		$1K Hold
108
– – ﹤0.01% 796
2022
Q2 		$1.23K Buy
+108
New +$959 ﹤0.01% 889
2022
Q1 		– Sell
-108
Closed -$2K – 315
2021
Q4 		$2K Hold
108
– – ﹤0.01% 888
2021
Q3 		$3K Hold
108
– – ﹤0.01% 901
2021
Q2 		$3K Buy
+108
New +$3.08K ﹤0.01% 787

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eagle Bay Advisors's ALLO Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 216 shares — an estimated $460 sold.

Eagle Bay Advisors first reported a position in ALLO in Q2 2021 and held it in 14 quarters. The position peaked at $3K in Q3 2021. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • Eagle Bay Advisors reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Eagle Bay Advisors sold 216 Allogene Therapeutics shares in Q1 2025, an estimated $460.
  • Eagle Bay Advisors first reported a position in Allogene Therapeutics in Q2 2021 and held it in 14 quarters.
  • Eagle Bay Advisors's Allogene Therapeutics position peaked at $3K in Q3 2021.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.